A cost-effectiveness analysis of anemia screening before erythropoietin in patients with end-stage renal disease

American Journal of Kidney Diseases

Volumn 29, Issue 5, 1997, Pages 651-657

  Hutchison, Florence N ^a   Jones, Walter J ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b NONE

Author keywords

Anemia; cost effectiveness; end stage renal disease; erythropoietin

Indexed keywords

ALUMINUM; CYANOCOBALAMIN; ERYTHROPOIETIN; FOLIC ACID; IRON; PARATHYROID HORMONE; TRANSFERRIN;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIAGNOSTIC VALUE; DRUG COST; DRUG RESPONSE; FEMALE; HEMATOCRIT; HUMAN; IRON DEFICIENCY ANEMIA; KIDNEY FAILURE; MALE; MEDICAL PRACTICE; SCREENING;

EID: 0030954014     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(97)90116-5     Document Type: Article

References (26)

1. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson J: Correction of anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316:73-78, 1987
2. Grutzmacher P, Bergmann M, Weinreich T, Natterman U, Reimers E, Pollok M: Beneficial and adverse effects of correction of anaemia by recombinant human erythropoietin in patients on maintenance hemodialysis, in Berlyne GM (ed): Contributions to Nephrology, vol 66. Basel, Switzerland, Karger, 1988, pp 104-113
3. Evans RW, Rader B, Manninen DL: The Cooperative Multicenter EPO Clinical Trial Group. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA 263:825-830, 1990
4. Human Recombinant Erythropoietin Utilization in the Department of Veterans Affairs Dialysis Centers. Milwaukee, WI, National Center for Cost Containment, Department of Veterans Affairs, November 1992
5. Van Wyck DB, Stivelman JC, Ruiz J, Kirlin LF, Katz MA, Ogden DA: Iron status in patients receiving erythropoietin for dialysis-associated anemia. Kidney Int 35:712-716, 1989
6. Tarng D-C, Chen TW, Huang T-P: Iron metabolism indices for early prediction of the response and resistance to erythropoietin therapy in maintenance hemodialysis patients. Am J Nephrol 15:230-237, 1995
7. Beguin BY, Loo M, R'Zik S, Sautois B, Lejeune F, Rorive G, Fillet G: Early prediction of response to recombinant human erythropoietin in patients with the anemia of renal failure by serum transferrin receptor and fibriniogen. Blood 82:2010-2016, 1993
8. Massry SG: Pathogenesis of the anemia of uremia: Role of secondary hyperparathyroidism. Kidney Int Suppl 16: S204-S207, 1983
9. Muirhead N, Hodsman AB, Hollomby DJ, Cordy PE: The role of aluminum and parathyroid hormone in erythropoietin resistance in hemodialysis patients. Nephrol Dial Transplant 6:342-345, 1991
10. Kleiner MJ, Van Wyck DB, Kaupke CJ, Kirlin LF: The role of iron and other factors in patients unresponsive to erythropoietin therapy. Semin Dial 8:29-34, 1995
11. Tietz NW: Biochemical aspects of hematology, in Fairbanks VF, Klee GG (eds): Textbook of Clinical Chemistry. Philadelphia, PA, Saunders, 1986, p 1582
12. Milliner DS, Nebeker HS, Ott SM, Andress DL, Sherrard DJ, Alfrey AC, Slatopolsky EA, Coburn JW: Use of the deferoxamine infusion test in the diagnosis of aluminum-related osteodystrophy. Ann Intern Med 101:775-780, 1984
13. Warner KE, Luce BR: Cost Benefit and Cost Effectiveness Analysis in Health Care. Ann Arbor, MI, Health Administration Press, 1982
14. Abels RI: Recombinant erythropoietin in the treatment of the anemia of cancer. Acta Haematol 87:4-11, 1992 (suppl 1)
15. Mohandas K, Aledort L: Transfusion requirement, risks, and costs for patients with malignancy. Transfusion 35:427-430, 1995
16. Maier RF, Obladen M, Scigall P, Linderkamp O, Duc G, Hieronimi G, Halliday HL, Versmold HT, Moriette G, Jorch G, Verellen G, Semmekrot BA, Grauel EL, Holland BM, Wardrop CA: The effect of epoetin beta (recombinant human erythropoietin) on the need for transfusion in very low birth weight infants. N Engl J Med 330:1173-1178, 1994
17. Meyer MP, Meyer JH, Commerford A, Kann FM, Sive AA, Molloer G, Jacobs P, Malan AF: Recombinant erythropoietin in the treatment of the anemia of prematurity: Results of a double-blind, placebo-controlled study. Pediatrics 93:918-923, 1994
18. Shireman TI, Hilsenrath PE, Strauss RG, Widness JA, Mutnick AH: Recombinant human erythropoietin vs transfusions in the treatment of anemia of prematurity. Arch Pediatr Adolesc Med 148:582-588, 1994
19. Ohls RK, Osborne KA, Christensen RD: Efficacy and cost analysis of treating very low birth weight infants with erythropoietin during their first two weeks of life: A randomized, placebo-controlled trial. J Pediatr 126:421-426, 1995
20. Bendani PL, Cecchetti E, Gilli P: Effectiveness of subcutaneous low-dose human erythropoietin in patients with chronic renal failure despite low serum ferritin. Nephron 71:459-460, 1995 (letter)
21. Casati S, Campise M, Ponticelli C: Correction of anaemia with recombinant human erythropoietin despite low serum ferritin. Nephrol Dial Transplant 6:452-456, 1991
22. Lee GR: Iron deficiency and iron-deficiency anemia, in Lee GR (ed): Wintrobe's Clinical Hematology (ed 9). Philadelphia, PA, Lea & Febiger, 1993, pp 808-839
23. Rao DS, Shih MS, Mohini R: Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 328:171-175, 1993
24. Pierratos A, Toor P, Ayiomamitis A, Oreopoulos D, Keating A: Immunoreactive parathyroid hormone and in vitro inhibition of erythropoiesis by uremic serum in patients on continuous ambulatory peritoneal dialysis. Am J Nephrol 6:465-468, 1986
25. McGonigle RJ, Wallin JD, Husserl F, Deftos LJ, Rice JC, O'Neil WJ Jr, Fisher JW: Potential role of parathyroid hormone as an inhibitor of erythropoiesis in the anemia of renal failure. J Lab Clin Med 104:1016-1026, 1984
26. Kalantar-Zadeh K, Hoffken B, Wunsch H, Fink H, Kleiner M, Luft FC: Diagnosis of iron deficiency in renal failure patients in the post-erythropoietin era. Am J Kidney Dis 26:292-299, 1995